SCHEMBL13638218

SCHEMBL13638218

COc1cc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C)ccc1I

nearest known ligand 0.84

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 19/20 0.84
EGFR P00533 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637916 0.91 BRD4 (0.69) BRD4
SCHEMBL17526080 0.91 BRD4 (1.00) BRD4EGFR
SCHEMBL30306426 0.91 BRD4 (1.00) BRD4EGFR
SCHEMBL13638219 0.90 BRD4 (0.68) BRD4
SCHEMBL30306536 0.89 BRD4 (1.00) BRD4
SCHEMBL265038 0.89 BRD4 (1.00) BRD4
SCHEMBL17526250 0.88 BRD4 (1.00) BRD4
SCHEMBL31163073 0.88 BRD4 (1.00) BRD4
SCHEMBL14389894 0.88 BRD4 (0.79) BRD4EGFR
SCHEMBL17526177 0.87 BRD4 (1.00) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 BRD4 142/4885EGFR 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.